Abstract
The proportional hazards assumption rarely holds in clinical trials of cancer immunotherapy. Specifically, delayed separation of the Kaplan-Meier survival curves and long-term survival have been observed. Routine practice in designing a randomized controlled two-arm clinical trial with a time-to-event endpoint assumes proportional hazards. If this assumption is violated, traditional methods could inaccurately estimate statistical power and study duration. This article addresses how to determine the sample size in the presence of nonproportional hazards (NPH) due to delayed separation, diminishing effects, etc. Simulations were performed to illustrate the relationship between power and the number of patients/events for different types of nonproportional hazards. Novel efficient algorithms are proposed to optimize the selection of a cost-effective sample size.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chen, T.T.: Statistical issues and challenges in immuno-oncology. J. Immuno. Ther. Canser. 1, 18 (2013). https://doi.org/10.1186/2051-1426-1-18
Ferris, R.L., Blumenschein Jr., G., Fayette, J., et al.: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016)
Fleming, T.R., Harrington, D.P., O’sullivan, M.: Supremum versions of the log-rank and generalized Wilcoxon statistics. J. Amer. Statist. Assoc. 82(397), 312–320 (1987)
Hoos, A.: Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 23(8), viii47–viii52 (2012)
Lakatos, E.: Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics, 229–241 (1988)
Lachin, J.M., Foulkes, M.A.: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics, 507–519 (1986)
Mok, T.S., Wu, Y.L., Thongprasert, S., et al.: Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009)
Robert, C., Thomas, L., Bondarenko, I., et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this paper
Cite this paper
Yang, M., Hua, Z., Vardhanabhuti, S. (2019). Sample Size Determination Under Non-proportional Hazards. In: Liu, R., Tsong, Y. (eds) Pharmaceutical Statistics. MBSW 2016. Springer Proceedings in Mathematics & Statistics, vol 218. Springer, Cham. https://doi.org/10.1007/978-3-319-67386-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-67386-8_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67385-1
Online ISBN: 978-3-319-67386-8
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)